KR20120058413A - Antibacterial Composition Containing Zanthoxylum schinifolium Extract - Google Patents

Abstract

PURPOSE: An antibacterial composition against helicobacter, containing Zanthoxylum schinifolium extract and bergapten or lupeol is provided to prevent and treat various gastric and duodenal diseases without irritation. CONSTITUTION: An antibacterial composition against helicobacter contains Zanthoxylum schinifolium extract as an active ingredient. The extract is prepared using alcohol of 1-4 carbon atoms or mixture solvent thereof. The helicobacteria include Helicobacter pylori, Helicobacter canis, Helicobacter cinaed, Helicobacter heilmannii, Helicobacter felis, Helicobacter mustelae, Helicobacter fenelliae, Helicobacter rappini, Helicobacter hepaticus, Helicobacter bilis, or Helicobacter pullorum. The antibacterial composition contains bergapten or lupeol as an active ingredient. The compounds are obtained from Helicobacter Zanthoxylum schinifolium. A pharmaceutical composition for preventing and treating gastric and duodenal diseases contains the extract. The pharmaceutical composition also contains bergapten or lupeol as an active ingredient.

Description

Antibacterial Composition Containing Acidic Extracts {Antibacterial Composition Containing Zanthoxylum schinifolium Extract}

The present invention relates to an antimicrobial composition against Helicobacter spp. Comprising Zanthoxylum schinifolium extract and bergapten or lupeol isolated therefrom as an active ingredient.

Helicobacter pylori isolated from Marshall's, Warren and Goodwin's gastric mucosa in Australia in 1982 caused hepatitis B, gastric ulcer and duodenal ulcer. It is known as the primary determinant. Among the pathogenesis of gastrointestinal and duodenal diseases caused by Helicobacter pylori infection, urease, a urease, is particularly important in inducing inflammation of the stomach. Helicobacter pylori produces urease, which is 6% of the total protein. The urease breaks down urea into ammonia and carbon dioxide, neutralizes the bacterial environment, and protects against gastric mucosa attack. Ammonia itself accumulates directly in the gastric mucosal epithelial cells, causing gastric mucosal damage (Sidebotham RL, et al., J. Clin. Pathol., 44, pp 52-57, 1991). Due to the action of this urease, gastric acid in the gastric lumens flows back down the mucosal layer, which causes gastric inflammation and gastric ulceration. In addition, ammonia itself inhibits oxygen consumption of gastric mucosa cells and ATP production in mitochondria (Tsujii M., et al., Gastroenterology, 102, pp 1881-1888, 1992), ultimately forming monochloroamine It has been reported to produce reactive oxygen pecies, causing cell damage, causing chronic inflammation, and further DNA damage, thereby promoting the cancer development process (Hahm KB, et al., Am. J. Gastroenterol). , 92, pp 1853-1857, 1997).

The transmission of Helicobacter is through animals or humans, or through various channels such as carelessness or food in medical practice (Dunn, BE, Cohen, H., and Blaser, MJ (1997). Clinical Microbiology Reviews, 10 (4) ), 720-7; Kodaira, MS, Escobar, AMU, & Grisi, S. (2002) Revista de Sade Pade Pblica. 36: 356-369), once infected, are not easily eradicated.

Helicobacter pylori-like bacteria that have been isolated from humans and animals to date are also known as Helicobacter pylori, Helicobacter canis, Helicobacter cinaedi, Helicobacter heilmann II, Helicobacter felis, Helicobacter mustelie, Helicobacter fenelliae, Helicobacter raffelli, Helicobacter hepaticus, Helicobacter bilis bacilli (Helicobacter bacilli) (Helicobacter pullorum) and the like are known.

Helicobacter pylori is specific to humans and is primarily found in certain places in the stomach, such as peptic ulcers (e.g. gastric or duodenal ulcers), inflammation (e.g. gastritis, etc.), diseases of the upper digestive tract such as gastric cancer, MALT (Mucosaassociated lymphoid tissue) Background of pathogenesis of lymphoma or chronic heart disease. At present, studies on the treatment of Helicobacter pylori infection have been actively conducted, and as a treatment method thereof, many reports for the purpose of removal and prevention of recurrence have been reported.

As described above, Helicobacter pylori is a very dangerous microorganism in gastrointestinal diseases, but there is a lack of development of appropriate antibacterial materials using natural materials. Current Helicobacter pylori treatments include general triple therapy, bismuth preparations, bismuth preparations, omeparazole and tetracycline in combination with bismuth preparations, metronidazole, and tetracycline or amoxicillin. And quadruple therapy with metronidazole. However, it has been pointed out that the emergence of resistant strains by antibiotic administration, the penetration of drugs in the stomach, and the regrowth of bacteria whose growth has been inhibited after treatment. For this reason, numerous efforts have been made to search for antimicrobial substances specific to Helicobacter pylori, and recently, interest in bioactive components in plants has increased, suggesting the possibility of their bioregulatory function and recovery or prevention of diseases. Has been. Recently, the antimicrobial activity of Helicobacter pylori of various natural products, such as thyme, Chinese tea, Cashew apple, joiner and rhubarb, has been reported, but the research is still insufficient.

Therefore, the discovery of antimicrobial material for Helicobacter pylori from abundant and easily available edible folk resources is an important material to replace antibiotics such as tetracycline. In particular, the antimicrobial agent against the most ideal Helicobacter pylori bacteria is not only an antibacterial role but also does not stimulate the epithelial cells.

In order to solve the problems described above, the inventors continue to search for natural antibacterial material having excellent antibacterial effect on Helicobacter without harming the stomach, while extracting and extracting bergapten from it Alternatively, the present invention has been completed by finding that lupeol has an antimicrobial effect against Helicobacter pylori bacteria present in the stomach.

An object of the present invention is to provide an antimicrobial composition against Helicobacter bacteria and a composition for the prevention and treatment of gastrointestinal and duodenal diseases caused by Helicobacter pylori.

In order to achieve the above object, the present invention provides an antimicrobial composition against Helicobacter bacterium comprising an acid extract as an active ingredient.

The present invention also provides an antimicrobial composition against Helicobacter bacteria comprising bergapten or lupeol as an active ingredient.

The present invention also provides a pharmaceutical composition for the prevention and treatment of gastrointestinal and duodenal diseases, including the extract of Sancho as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing and treating gastrointestinal and duodenal diseases, including bergapten or lupeol as an active ingredient.

In another aspect, the present invention provides a health functional food for the prevention and improvement of gastric and duodenal disease comprising an extract of the extract as an active ingredient.

In another aspect, the present invention provides a dietary supplement for preventing and improving gastrointestinal and duodenal diseases, including bergapten or lupeol as an active ingredient.

The antimicrobial sancho extract of the present invention and bergapten or lupeol isolated therefrom exhibit antimicrobial activity to Helicobacter pylori, but do not irritate the stomach, preventing and preventing various gastrointestinal diseases caused by Helicobacter pylori. It is useful for treatment.

Figure 1 is a schematic diagram of the fraction of the extract.
Figure 2 is the antimicrobial activity of the methanol extract of Sancho.
Figure 3 shows the antimicrobial activity of the acid fraction.
Figure 4 shows the antimicrobial activity of bergapten or lupeol isolated from the extracts.

Hereinafter, the present invention will be described in more detail.

In one embodiment, the present invention provides an antimicrobial composition against Helicobacter bacterium comprising an acid extract as an active ingredient.

Japanese vine is the scientific name of Zanthoxylum schinifolium ) is a plant belonging to the Unhyangdae family, also called branched or lettuce. It is widely grown in Northeast Asia such as Korea, Japan, and China, and the bark, leaves, and fruits of Japanese pepper are used for spice, medicinal and oil-making (Lee Jong-won (1998), The Korean Society of Food and Nutrition, 11 (5), p493-498).

As used herein, the term "extract" refers to an active ingredient isolated from natural products, that is, a material that exhibits the desired activity. The extract may be obtained by an extraction process using water, an organic solvent or a mixed solvent thereof, and includes the dry powder thereof or any form formulated using the extract. In addition, the extract also includes a fraction obtained by the extraction through the extraction process.

Sancho extract according to the present invention can be obtained through the following process.

The extracting portion of the herb is not limited thereto, but branch or leaf of the herb is preferable. The acetic acid is extracted with one or more solvents selected from the group consisting of alcohol, ethyl acetate, chloroform, methyl ethyl ketone, acetone and ether and concentrated under reduced pressure. The alcohol may be a lower or higher alcohol, preferably a lower alcohol selected from the group consisting of methanol, ethanol, isopropanol and butanol, more preferably methanol. The alcohol may be a mixture with water. In addition to the concentrate, hexane, methyl chloride, ethyl acetate, butanol or water may be fractionated and concentrated under reduced pressure again. The fractional concentrate may be further purified by chromatography (paper, TLC, column, etc.) using silica or paper as a carrier, and a mixed solution of chloroform: acetone: formic acid as a developing solvent. have. Here, the distribution of the substances in the extract between the water contained in the carrier and the developing solvent occurs, and the substances are separated according to the difference in distribution ratio. Chloroform: acetone: formic acid in the developing solvent may be mixed in a ratio of 50-100: 10-20: 5-10, most preferably 75: 16.5: 8.5. The chromatography may be thin layer chromatography (TLC) or column chromatography using silica as a carrier. The TLC is a method of applying a thin coating of silica gel to a support such as a glass plate or plastic, dropping the extract thereon and then developing with a developing solvent to purify. In the column chromatography, silica is packed into a column, an extract is loaded thereon, and then purified by developing with a developing solvent. It is preferable to use column chromatography for mass production of the extract.

The Helicobacter bacteria of the present invention is not particularly limited and may include all bacteria included in Helicobacter spp. Helicobacter cinaedi, Helicobacter heilmannii, Helicobacter felis, Helicobacter mustelae, Helicobacter helielli, Helicobacter helicobacterii Helicobacter hepaticus, Helicobacter bilis (Helicobacter bilis), Helicobacter pullorum (Helicobacter pullorum) may be selected from bacteria.

The present invention also provides an antimicrobial composition against Helicobacter bacteria comprising bergapten or lupeol as an active ingredient. Bergapten has the structure of Formula 1, and lupeol has the structure of Formula 2. The bergapten or lupeol can be obtained from the extract of the herb and can be used synthetically or purchased from the manufacturer.

In another aspect, the present invention provides a pharmaceutical composition for the prevention and treatment of gastrointestinal and duodenal diseases, including an extract of Sancho as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing and treating gastrointestinal and duodenal diseases, including bergapten or lupeol as an active ingredient.

The gastric and duodenal diseases are caused by Helicobacter pylori, mean a disease occurring in the stomach or duodenal region, and may include peptic ulcer and gastric cancer, preferably gastritis, duodenitis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma It may be at least one selected from the group consisting of gastric lymphoma and gastric cancer, the gastritis may preferably be chronic atrophic gastritis. Since the discovery of Helicobacter pylori, the main causative agent of gastric and duodenal diseases has been reported as Helicobacter pylori, Helicobacter pylori is known to inhabit mainly by binding to the gastric mucosa, specifically epithelial cells and mucosal layers. Therefore, in order to treat the stomach and duodenal disease, it is possible to prescribe an excellent antimicrobial activity against the causative bacterium Helicobacter pylori.

The pharmaceutical compositions of the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral dosage forms, sterile injectable solutions, suppositories, and transdermal formulations according to conventional methods. have. Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. If necessary, it is formulated with diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like.

In one embodiment, the pharmaceutical compositions of the present invention may be formulated as a solid preparation for oral administration. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which include at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like. It is formulated by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

In another embodiment, the pharmaceutical compositions of the present invention may be formulated into liquid preparations for oral administration. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups, and the like. In addition to conventional inert diluents (e.g., purified water, ethanol, liquid paraffin), various excipients may be used. Wetting agents, sweetening agents, fragrances, preservatives and the like can be included.

In another embodiment, the pharmaceutical compositions of the present invention may be formulated into preparations for parenteral, preferably intraperitoneal administration. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As a sterile aqueous solution, suitable buffer solutions such as Hanks' solution, Ringer's solution, or physically buffered saline can be used.For non-aqueous solvents, suspensions include propylene glycol, polyethylene glycol, olive oil, Same vegetable oils, injectable esters such as ethyloleate, and the like can be used. If necessary, preservatives, stabilizers, wetting or emulsifying agents, salts for controlling osmotic pressure and / or buffers may also be used. On the other hand, suppositories, such as witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, and the like may be used.

Compositions formulated in such a manner can be administered in various amounts, including parenteral or oral (dermal, subcutaneous, intravenous, intramuscular, intraperitoneal) in an effective amount. As used herein, an "effective amount" refers to an amount exhibiting a prophylactic or therapeutic effect when administered to a patient. The dosage of the composition according to the present invention may be appropriately selected depending on the route of administration, subject of administration, age, sex, weight, individual difference and disease state. Preferably, the composition of the present invention may vary the content of the active ingredient depending on the degree of disease, preferably 0.1 to 10000 mg / kg / day, more preferably 10 ~ 1000 mg / kg / day It may be administered in an effective amount of.

As another aspect, the present invention provides a dietary supplement for preventing and improving gastrointestinal and duodenal diseases, including an extract of Sancho as an active ingredient.

In another aspect, the present invention provides a dietary supplement for preventing and improving gastrointestinal and duodenal diseases, including bergapten or lupeol as an active ingredient.

 When the composition of the present invention is used as a food or beverage additive, the above extract or Bergapten or lupeol may be added as it is, or used together with other food or food ingredients, and used appropriately according to conventional methods. Can be. The mixed amount of the acid extract or bergapten or lupeol may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).

In the case of prolonged ingestion for health or health control, long-term administration is possible because the sancho extract has no problem in terms of safety.

There is no particular limitation on the kind of the food. Examples of the food to which the substance may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, and drinks. Alcoholic beverages and vitamin complexes.

The liquid component added in addition to the antimicrobial sancho extract when formulated into a beverage is not limited to the above, but may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in conventional beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides (e.g. glucose, fructose and the like), disaccharides (e.g. maltose, sucrose and the like) and polysaccharides (e.g. conventional sugars such as dextrin, cyclodextrin and the like), and xylitol Sugar alcohols such as sorbitol and erythritol. The proportion of said natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention. As flavoring agents other than those mentioned above, natural flavoring agents (for example, taumarin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be used. .

In another embodiment, the food composition of the present invention comprises various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, organic acids , Protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The food composition of the present invention may also contain pulp for the production of fruit and vegetable drinks. These ingredients may be used alone or in combination, and the proportion of such additives may be selected in the range of 10 to 20% by weight, based on the total weight of the composition.

Hereinafter, preferred examples and preparation examples are provided to aid in understanding the present invention. However, the following examples and preparations are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples and preparations.

Example  1. Methanol and Fraction  purchase

After drying the acid was extracted systematically using methanol (methanol) and extracted three times or more, and then concentrated under reduced pressure (CCA-1100, EYELA) at 40 ℃ under reduced pressure, to give a methanol extract of acid.

The methanol extract was partitioned into hexane, methylene chloride, ethyl acetate, butanol or water, respectively, to obtain an acidic fraction. Fractional schematics are shown in FIG. 1.

Example  2. Helicobacter Pylori  Antimicrobial effect test

Helicobacter pylori, a causative agent of stomach and duodenal ulcers, is a Helicobacter pylori strain 26695, which is available from Helicobacter pylori isolated strain banks for optimal culture of bacteria (Brucella Broth 0.56g <Pancreatic digest of casein 0.2g, dextrose 0.2g, Yeast) extract 0.04 g, sodium chloride 0.1 g, sodium bisulfate 0.002 g>, agar 0.24 g, Horse serum 2 mL). In order to maintain aerobic conditions, the culture was maintained at 95% or more in a 10% CO ₂ incubator. Incubation on an agar plate was carried out at 37 ° C. for 48-72 hours.

Dispense 100 μL of the homogenous solution into a Helicobacter Pylori optimal medium plate, spread it with a sterile glass rod, place sterilized disc paper (8 mm in diameter), concentrate each extract sterilized with a 0.45 μm membrane filter, and dilute with sterile water. 30μL of each extract of various concentrations was absorbed into disc paper, and the control was absorbed in sterile water and then incubated for 24 hours at 37 ° C. in aerobic conditions, and then the presence of clear zones around the disc was confirmed.

2.1. Antimicrobial Activity of Methanol Extract

As a result of examining the antimicrobial effect of Helicobacter pylori bacteria of methanol extract of Sancho, as shown in Fig. 2, the clear zone was 8 mm in sterile water, which showed no antimicrobial effect of Helicobacter pylori, but the concentration of 10 μg / 30μL 30 μL of vinegar, or 10 μg of vinegar, had a clear zone of 17 mm, confirming the antimicrobial effect against Helicobacter pylori.

2.2. Of Sancho methanol extract Fraction  And antimicrobial activity of active ingredients

In order to confirm the active ingredient exhibiting the antimicrobial activity against Helicobacter pylori bacteria, after extracting the methanol extract of the vinegar with an organic solvent (Fig. 1), the antimicrobial activity in the fractionation layer was confirmed. Experimental results, as shown in Figure 3, the acid fractions Hx, MC, EtOAc, BuOH is E. coli The antimicrobial activity of S. aureus against S. aureus was not shown, but H. pylori Hx and MC fractions showed inhibitory effects of 11 mm and 10 mm, respectively.

Based on the experimental results, bergapten and lupeol showing antimicrobial activity from the active fraction MC fractions were identified through TLC. The structure was identified through NMR, and shown in the following formula (1) and (2).

Bergapten; ¹ H-NMR (500 MHz, CDCl ₃ ): δ 4.26 (3H, s, OMe), 6.26 (1H, d, J = 9.5 Hz, H-3), 7.02 (1H, s, H-3 '), 7.12 (1 H, s, H-8), 7.59 (1H, s, H-2 '), 8.14 (1H, d, J = 9.5 Hz, H-4)

 [Formula 1]

Lupeol; ¹ H-NMR (500 MHz, CDCl ₃ ): δ 0.76 (3H, s, H-28), 0.79 (3H, s, H-23), 0.83 (3H, s, H-25), 0.94 (3H, s, H-24), 0.97 (3H, s, H-27), 1.03 (3H, s, H-26), 1.68 (3H, s, H-30), 2.38 (1H, dd, J = 5.2, 11.0 Hz, H-19), 3.19 (1H, br d, J = 11.0 Hz, H-3), 4.56 (1H, br s, H-29b), 4.68 (1H, br s, H-29a)

 [Formula 2]

As a result of confirming the antimicrobial activity of bergapten and lupeol, which are active substances obtained from the MC fraction layer, bergapten is 11 mm growth inhibitory ring, lupeol against Helicobacter pylori ) Shows a large growth inhibition ring of 12 mm (FIG. 4).

Therefore, it was confirmed through the present experiment that the extracts of native Korean native plants and the active ingredients isolated from the bergapten (bergapten) and lupeol (lupeol) showed excellent antimicrobial activity against Helicobacter pylori, such antimicrobial activity On the basis of this, it was confirmed that it can be used as a preventive and therapeutic agent for gastrointestinal diseases caused by Helicobacter pylori.

Hereinafter will be described a pharmaceutical composition comprising the composition of the present invention and a preparation example of a health functional food, the present invention is not intended to limit this but only to be described in detail.

Formulation example  One. Powder  Produce

2 ounces of extract or vergatten or lupeol

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

Sancho extract or Vergatten or Rufeol 100 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation example  3. Preparation of capsules

Sancho extract or Vergatten or Rufeol 100 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

Sancho extract or Vergatten or Rufeol 100 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO _{4 ?} 2H ₂ O 26 mg

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation example  5. Liquid  Produce

Sancho extract or Vergatten or Rufeol 100 mg

10 g per isomer

5 g mannitol

Purified water quantity

After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding a proper amount of lemon aroma, and then mixing the above components, adding purified water and adjusting the whole to 100 ml by adding purified water and filling into a brown bottle. The solution is prepared by sterilization.

Formulation example  6. Manufacture of health food

1 g of pepper extract or bergapten or lufeol

Vitamin mixture quantity

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

Biotin 10 μg

Nicotinamide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

15 mg potassium monophosphate

Dicalcium Phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation example  7. Health drink  Produce

1 g of pepper extract or bergapten or lufeol

15 g of vitamin C

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3g

Water quantification

After mixing the above components according to the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 l container, sealed sterilization and refrigerated and then Used to prepare the healthy beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (10)

Antimicrobial composition against Helicobacter bacterium comprising an extract of Zanthoxylum schinifolium as an active ingredient.
The composition of claim 1, wherein the extract is extracted with an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
According to claim 1, wherein the Helicobacter bacteria Helicobacter pylori (Helicobacter pylori), Helicobacter canis (Helicobacter canis), Helicobacter cinaedi, Helicobacter Heilmanii (Helicobacter heilmannii), Helicobacter bacilli Felis Helicobacter mustelae, Helicobacter fenelliae, Helicobacter raffini, Helicobacter hepaticus, Helicobacter billis (Helicobacter bilis) and Helicobacter pools Composition characterized in that the strain selected from the group.
Antimicrobial composition against Helicobacter bacterium comprising bergapten or lupeol as an active ingredient.
5. A composition according to claim 4, wherein the bergapten or lupeol is obtained from the herb.
A pharmaceutical composition for preventing and treating gastrointestinal and duodenal diseases, which comprises an extract of the extract as an active ingredient.
The composition of claim 6, wherein the gastric and duodenal diseases are diseases selected from the group consisting of gastritis, duodenitis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma, gastric lymphoma and gastric cancer caused by Helicobacter pylori.
A pharmaceutical composition for preventing and treating gastrointestinal and duodenal diseases, including bergapten or lupeol as an active ingredient.
Health functional food for preventing and improving gastrointestinal and duodenal diseases, including bergapten or lupeol as an active ingredient.
Health functional food for preventing and improving gastrointestinal and duodenal disease, which contains an extract of the extract as an active ingredient.

Images